HighTide Therapeutics (HKG:2511) booked a loss attributable to owners of 120.3 million yuan for the first half of 2025, compared with a loss of 211 million yuan a year earlier, according to a Monday Hong Kong bourse filing.
Shares of the biopharmaceutical firm gained over 7% in Tuesday late-afternoon trade.
Loss per share came in at 0.27 yuan, compared with 0.47 yuan in the prior-year period.
The company said that no revenue was derived during the six months ended June 30.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。